

You are invited to a presentation on:

Korlym Treatment: Taking Control of Patient Management

Tuesday, September 29, 2026

6:15 PM Eastern Time

LOCATION:

The Grille @ 1951
1951 South Tamiami Trail
Port Charlotte, FL 33948
(860) 867-6688

PRESENTED BY:

Dana Cruse, CFNP, BC-ADM
Mountain State Diabetes
Parkersburg, WV

HOSTED BY:

Corcept Therapeutics
Kelly Gamble
(937) 684-0866
kgamble@corcept.com

THREE WAYS TO REGISTER

1. Click button to register

REGISTER NOW

2. Enter the following link into your web browser <https://rsvp.corceptportal.com>

3. Open the Camera app on your mobile device and hold your device over the QR code. Tap the notification to open the link to register.

The information you provide will be used only to facilitate your attendance at the program. We look forward to your participation in this informative discussion.



ENTER MEETING ID:
1094

INDICATION

KORLYM (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

Limitations of use: KORLYM should not be used in the treatment of patients with type 2 diabetes unless it is secondary to Cushing's syndrome.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: TERMINATION OF PREGNANCY

Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively. The antiprogesterational effects will result in the termination of pregnancy. Pregnancy must therefore be excluded before the initiation of treatment with Korlym and prevented during treatment and for one month after stopping treatment by the use of a nonhormonal medically acceptable method of contraception unless the patient has had a surgical sterilization, in which case no additional contraception is needed. Pregnancy must also be excluded if treatment is interrupted for more than 14 days in females of reproductive potential.

Please see additional Important Safety Information on next page, and full Prescribing Information, including BOXED WARNING.